CPRX
Catalyst Pharmaceuticals, Inc.
Biotechnology
Market Cap$3.74B
5Y Perf.+608.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CPRX vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.55B
5Y Perf.-62.1%
CPRX vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CPRX | RARE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $3.74B | $2.55B |
| Revenue (TTM) | $589M | $669M |
| Net Income (TTM) | $214M | $-609M |
| Gross Margin | 85.2% | 83.6% |
| Operating Margin | 43.8% | -83.9% |
| Forward P/E | 16.2x | — |
| Total Debt | $2M | $1.28B |
| Cash & Equiv. | $709M | $434M |
CPRX vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CPRX
RARE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Catalyst Pharmaceut… (CPRX) | 100 | 708.1 | +608.1% |
| Ultragenyx Pharmace… (RARE) | 100 | 37.9 | -62.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CPRX vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CPRX leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Ultragenyx Pharmaceutical Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
CPRX
Catalyst Pharmaceuticals, Inc.
The Income Pick
CPRX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.88
- Rev growth 19.8%, EPS growth 28.2%, 3Y rev CAGR 40.1%
- 49.2% 10Y total return vs RARE's -58.9%
Best for: income & stability and growth exposure
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Leader
RARE is the clearest fit if your priority is growth.
- 20.1% revenue growth vs CPRX's 19.8%
Best for: growth
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RARE | 20.1% revenue growth vs CPRX's 19.8% |
| Quality / Margins | CPRX | 36.4% margin vs RARE's -91.0% |
| Stability / Safety | CPRX | Beta 0.88 vs RARE's 1.42 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CPRX | +32.4% vs RARE's -26.0% |
| Efficiency (ROA) | CPRX | 19.4% ROA vs RARE's -45.8%, ROIC 83.9% vs -89.4% |
CPRX vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
CPRX vs RARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCPRXLAGGINGRARE
RAREUltragenyx Pharmaceut…
1leads
CPRXCatalyst Pharmaceutic…
4leads
6 Total Categories
CATEGORYLEADERvs RAREMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CPRX6/6
Valuation MetricsMultiples, price ratios, and targets
RARE2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CPRX6/6
Total Returns1Y, 3Y, 5Y total returns with dividends
CPRX6/6
Risk & VolatilityBeta, volatility, and downside exposure
CPRX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CPRX leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RARE and CPRX operate at a comparable scale, with $669M and $589M in trailing revenue. CPRX is the more profitable business, keeping 36.4% of every revenue dollar as net income compared to RARE's -91.0%. On growth, CPRX holds the edge at +7.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CPRXCatalyst Pharmace… | RAREUltragenyx Pharma… |
|---|---|---|
| RevenueTrailing 12 months | $589M | $669M |
| EBITDAEarnings before interest/tax | $295M | -$536M |
| Net IncomeAfter-tax profit | $214M | -$609M |
| Free Cash FlowCash after capex | $209M | -$487M |
| Gross MarginGross profit ÷ Revenue | +85.2% | +83.6% |
| Operating MarginEBIT ÷ Revenue | +43.8% | -83.9% |
| Net MarginNet income ÷ Revenue | +36.4% | -91.0% |
| FCF MarginFCF ÷ Revenue | +35.4% | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.6% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -9.1% | -17.2% |
CPRX leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
RARE leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | CPRXCatalyst Pharmace… | RAREUltragenyx Pharma… |
|---|---|---|
| Market CapShares × price | $3.7B | $2.5B |
| Enterprise ValueMkt cap + debt − cash | $3.0B | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | 18.17x | -4.45x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.23x | — |
| PEG RatioP/E ÷ EPS growth rate | 0.97x | — |
| EV / EBITDAEnterprise value multiple | 10.27x | — |
| Price / SalesMarket cap ÷ Revenue | 6.35x | 3.79x |
| Price / BookPrice ÷ Book value/share | 4.07x | — |
| Price / FCFMarket cap ÷ FCF | 17.92x | — |
RARE leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
CPRX leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
CPRX delivers a 22.5% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-6 for RARE.
| Metric | CPRXCatalyst Pharmace… | RAREUltragenyx Pharma… |
|---|---|---|
| ROE (TTM)Return on equity | +22.5% | -6.1% |
| ROA (TTM)Return on assets | +19.4% | -45.8% |
| ROICReturn on invested capital | +83.9% | -89.4% |
| ROCEReturn on capital employed | +30.6% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.00x | — |
| Net DebtTotal debt minus cash | -$707M | $842M |
| Cash & Equiv.Liquid assets | $709M | $434M |
| Total DebtShort + long-term debt | $2M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | — | -14.49x |
CPRX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
CPRX leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CPRX five years ago would be worth $65,353 today (with dividends reinvested), compared to $2,241 for RARE. Over the past 12 months, CPRX leads with a +32.4% total return vs RARE's -26.0%. The 3-year compound annual growth rate (CAGR) favors CPRX at 20.7% vs RARE's -18.0% — a key indicator of consistent wealth creation.
| Metric | CPRXCatalyst Pharmace… | RAREUltragenyx Pharma… |
|---|---|---|
| YTD ReturnYear-to-date | +31.8% | +9.9% |
| 1-Year ReturnPast 12 months | +32.4% | -26.0% |
| 3-Year ReturnCumulative with dividends | +75.7% | -44.9% |
| 5-Year ReturnCumulative with dividends | +553.5% | -77.6% |
| 10-Year ReturnCumulative with dividends | +4915.6% | -58.9% |
| CAGR (3Y)Annualised 3-year return | +20.7% | -18.0% |
CPRX leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
CPRX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CPRX is the less volatile stock with a 0.88 beta — it tends to amplify market swings less than RARE's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CPRX currently trades 93.7% from its 52-week high vs RARE's 61.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CPRXCatalyst Pharmace… | RAREUltragenyx Pharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.88x | 1.42x |
| 52-Week HighHighest price in past year | $32.56 | $42.37 |
| 52-Week LowLowest price in past year | $19.05 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +93.7% | +61.2% |
| RSI (14)Momentum oscillator 0–100 | 74.2 | 61.0 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 1.8M |
CPRX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CPRX as "Buy" and RARE as "Buy". Consensus price targets imply 98.6% upside for RARE (target: $52) vs 8.1% for CPRX (target: $33).
| Metric | CPRXCatalyst Pharmace… | RAREUltragenyx Pharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $33.00 | $51.50 |
| # AnalystsCovering analysts | 16 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.7% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CPRX leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RARE leads in 1 (Valuation Metrics).
Best OverallCatalyst Pharmaceuticals, I… (CPRX)Leads 4 of 6 categories
Loading custom metrics...
CPRX vs RARE: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CPRX or RARE a better buy right now?
For growth investors, Ultragenyx Pharmaceutical Inc.
(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus 19. 8% for Catalyst Pharmaceuticals, Inc. (CPRX). Catalyst Pharmaceuticals, Inc. (CPRX) offers the better valuation at 18. 2x trailing P/E (16. 2x forward), making it the more compelling value choice. Analysts rate Catalyst Pharmaceuticals, Inc. (CPRX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CPRX or RARE?
Over the past 5 years, Catalyst Pharmaceuticals, Inc.
(CPRX) delivered a total return of +553. 5%, compared to -77. 6% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: CPRX returned +49. 2% versus RARE's -58. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CPRX or RARE?
By beta (market sensitivity over 5 years), Catalyst Pharmaceuticals, Inc.
(CPRX) is the lower-risk stock at 0. 88β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 61% more volatile than CPRX relative to the S&P 500.
04Which is growing faster — CPRX or RARE?
By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.
(RARE) is pulling ahead at 20. 1% versus 19. 8% for Catalyst Pharmaceuticals, Inc. (CPRX). On earnings-per-share growth, the picture is similar: Catalyst Pharmaceuticals, Inc. grew EPS 28. 2% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, CPRX leads at 40. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CPRX or RARE?
Catalyst Pharmaceuticals, Inc.
(CPRX) is the more profitable company, earning 36. 4% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 36. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CPRX leads at 43. 8% versus -79. 5% for RARE. At the gross margin level — before operating expenses — CPRX leads at 85. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CPRX or RARE more undervalued right now?
Analyst consensus price targets imply the most upside for RARE: 98.
6% to $51. 50.
07Which pays a better dividend — CPRX or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is CPRX or RARE better for a retirement portfolio?
For long-horizon retirement investors, Catalyst Pharmaceuticals, Inc.
(CPRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 88)). Both have compounded well over 10 years (CPRX: +49. 2%, RARE: -58. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CPRX and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(CPRX: 7.6% · RARE: -2.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.